Rasagiline is a strong, selective, and irreversible inhibitor of monoamine oxidase type-B (MAO-B) which is used as monotherapy or as add-on to levodopa in PD patients for its effects on prolonging the duration of action of both endogenously and exogenously derived dopamine [7]. Here, MAOB is linked to Parkinson disease.